Elimination of Antibiotic Resistant Surgical Implant Biofilms Using an Engineered Cationic Amphipathic Peptide WLBU2

Jonathan B. Mandell, Berthony Deslouches, Ronald C. Montelaro, Robert M.Q. Shanks, Yohei Doi, Kenneth L. Urish

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Antibiotics are unable to remove biofilms from surgical implants. This high antibiotic tolerance is related to bacterial persisters, a sub-population of bacteria phenotypically tolerant to antibiotics secondary to a reduced metabolic state. WLBU2 is an engineered cationic amphipathic peptide designed to maximize antimicrobial activity with minimal mammalian cell toxicity. The objective of this study was to test the ability of WLBU2 to remove Staphylococcus aureus surgical implant biofilms. WLBU2 effectively treated S. aureus biofilms formed by a variety of clinical MSSA and MRSA strains and created culture-negative implants in the in vitro biofilm model. Blocking bacterial metabolism by inhibiting oxidative phosphorylation did not affect WLBU2 killing compared to decreased killing by cefazolin. In the surgical implant infection animal model, WLBU2 decreased biofilm mass as compared to control, untreated samples. WLBU2 could rapidly eliminate implants in vitro and had sufficient efficacy in vivo with minimal systemic toxicity.

Original languageEnglish
Article number18098
JournalScientific reports
Volume7
Issue number1
DOIs
Publication statusPublished - 01-12-2017

Fingerprint

Biofilms
Anti-Bacterial Agents
Staphylococcus aureus
Cefazolin
Oxidative Phosphorylation
Methicillin-Resistant Staphylococcus aureus
Animal Models
WLBU2 peptide
Bacteria
Peptides
Infection
Population
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • General

Cite this

Mandell, Jonathan B. ; Deslouches, Berthony ; Montelaro, Ronald C. ; Shanks, Robert M.Q. ; Doi, Yohei ; Urish, Kenneth L. / Elimination of Antibiotic Resistant Surgical Implant Biofilms Using an Engineered Cationic Amphipathic Peptide WLBU2. In: Scientific reports. 2017 ; Vol. 7, No. 1.
@article{5f98433f3b8546399fd69ecd69d5ebcf,
title = "Elimination of Antibiotic Resistant Surgical Implant Biofilms Using an Engineered Cationic Amphipathic Peptide WLBU2",
abstract = "Antibiotics are unable to remove biofilms from surgical implants. This high antibiotic tolerance is related to bacterial persisters, a sub-population of bacteria phenotypically tolerant to antibiotics secondary to a reduced metabolic state. WLBU2 is an engineered cationic amphipathic peptide designed to maximize antimicrobial activity with minimal mammalian cell toxicity. The objective of this study was to test the ability of WLBU2 to remove Staphylococcus aureus surgical implant biofilms. WLBU2 effectively treated S. aureus biofilms formed by a variety of clinical MSSA and MRSA strains and created culture-negative implants in the in vitro biofilm model. Blocking bacterial metabolism by inhibiting oxidative phosphorylation did not affect WLBU2 killing compared to decreased killing by cefazolin. In the surgical implant infection animal model, WLBU2 decreased biofilm mass as compared to control, untreated samples. WLBU2 could rapidly eliminate implants in vitro and had sufficient efficacy in vivo with minimal systemic toxicity.",
author = "Mandell, {Jonathan B.} and Berthony Deslouches and Montelaro, {Ronald C.} and Shanks, {Robert M.Q.} and Yohei Doi and Urish, {Kenneth L.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-17780-6",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Elimination of Antibiotic Resistant Surgical Implant Biofilms Using an Engineered Cationic Amphipathic Peptide WLBU2. / Mandell, Jonathan B.; Deslouches, Berthony; Montelaro, Ronald C.; Shanks, Robert M.Q.; Doi, Yohei; Urish, Kenneth L.

In: Scientific reports, Vol. 7, No. 1, 18098, 01.12.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Elimination of Antibiotic Resistant Surgical Implant Biofilms Using an Engineered Cationic Amphipathic Peptide WLBU2

AU - Mandell, Jonathan B.

AU - Deslouches, Berthony

AU - Montelaro, Ronald C.

AU - Shanks, Robert M.Q.

AU - Doi, Yohei

AU - Urish, Kenneth L.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Antibiotics are unable to remove biofilms from surgical implants. This high antibiotic tolerance is related to bacterial persisters, a sub-population of bacteria phenotypically tolerant to antibiotics secondary to a reduced metabolic state. WLBU2 is an engineered cationic amphipathic peptide designed to maximize antimicrobial activity with minimal mammalian cell toxicity. The objective of this study was to test the ability of WLBU2 to remove Staphylococcus aureus surgical implant biofilms. WLBU2 effectively treated S. aureus biofilms formed by a variety of clinical MSSA and MRSA strains and created culture-negative implants in the in vitro biofilm model. Blocking bacterial metabolism by inhibiting oxidative phosphorylation did not affect WLBU2 killing compared to decreased killing by cefazolin. In the surgical implant infection animal model, WLBU2 decreased biofilm mass as compared to control, untreated samples. WLBU2 could rapidly eliminate implants in vitro and had sufficient efficacy in vivo with minimal systemic toxicity.

AB - Antibiotics are unable to remove biofilms from surgical implants. This high antibiotic tolerance is related to bacterial persisters, a sub-population of bacteria phenotypically tolerant to antibiotics secondary to a reduced metabolic state. WLBU2 is an engineered cationic amphipathic peptide designed to maximize antimicrobial activity with minimal mammalian cell toxicity. The objective of this study was to test the ability of WLBU2 to remove Staphylococcus aureus surgical implant biofilms. WLBU2 effectively treated S. aureus biofilms formed by a variety of clinical MSSA and MRSA strains and created culture-negative implants in the in vitro biofilm model. Blocking bacterial metabolism by inhibiting oxidative phosphorylation did not affect WLBU2 killing compared to decreased killing by cefazolin. In the surgical implant infection animal model, WLBU2 decreased biofilm mass as compared to control, untreated samples. WLBU2 could rapidly eliminate implants in vitro and had sufficient efficacy in vivo with minimal systemic toxicity.

UR - http://www.scopus.com/inward/record.url?scp=85039163450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039163450&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-17780-6

DO - 10.1038/s41598-017-17780-6

M3 - Article

C2 - 29273750

AN - SCOPUS:85039163450

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 18098

ER -